Evidence map›Paper›PMID 42078313›Full record

ArticleCancer diagnosis & prognosis

Current Status and Challenges of

Kayono Onishi, Yoshiya Horimoto, Kazuyo Kiribayashi, Yoichi Koyama, Kyoko Orimoto, Natsuki Uenaka, Hiroki Kusama, Takahiko Kawate, Kimito Yamada, Hiroshi Kaise and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kayono OnishiDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Yoshiya HorimotoDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Kazuyo KiribayashiDepartment of Clinical Genetics Center, Tokyo Medical University, Tokyo, Japan.
Yoichi KoyamaDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Kyoko OrimotoDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Natsuki UenakaDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Hiroki KusamaDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Takahiko KawateDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Kimito YamadaDepartment of Breast Surgical Oncology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Hiroshi KaiseDepartment of Breast Surgical Oncology, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
Natsuko InagakiDepartment of Clinical Genetics Center, Tokyo Medical University, Tokyo, Japan.
Takashi IshikawaDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: In patients with breast cancer, breast cancer gene 1 and 2 ( Patients and Methods: We analyzed 354 patients with breast cancer who underwent insurance-covered Results: Of the 354 patients, 238 (67.3%) were newly diagnosed, 60 (16.9%) were in postoperative follow-up, and 56 (15.8%) underwent companion diagnostic testing. Overall, 43 patients (12.1%) harbored pathogenic Conclusion: The higher prevalence of pathogenic

Indexed as

BRCA1/2 pathogenic variantsbreast cancergermline genetic testinghereditary breast and ovarian cancer (HBOC)testing implementation

Identifiers

PMID42078313
PMCPMC13133754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.